Entrada Therapeutics Analyst Ratings
Oppenheimer Initiates Entrada Therapeutics(TRDA.US) With Buy Rating, Announces Target Price $25
TD Cowen Maintains Entrada Therapeutics(TRDA.US) With Buy Rating
H.C. Wainwright Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $18
Entrada Therapeutics Analyst Ratings
Buy Rating Affirmed for Entrada Therapeutics on Strong Clinical Trial Data and Regulatory Prospects
TD Cowen Maintains Entrada Therapeutics(TRDA.US) With Buy Rating
TD Cowen Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)
Entrada Therapeutics Analyst Ratings
Entrada Therapeutics Analyst Ratings
TD Cowen Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)
Oppenheimer Initiates Coverage On Entrada Therapeutics With Outperform Rating, Announces Price Target of $22
Entrada Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Entrada Therapeutics, Lowers Price Target to $20
Entrada Therapeutics Analyst Ratings
Positive Prospects for Entrada Therapeutics Despite FDA Hold: An Analyst's Buy Rating Justification
Entrada Therapeutics' Promising Phase 1 Trial and Broad Tissue Distribution Profile Underpin Buy Rating
TD Cowen Remains a Buy on Entrada Therapeutics Inc (TRDA)
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $25 Price Target
Entrada Therapeutics Analyst Ratings